多生物标志物覆盖不同通路预测缺血性卒中结局
该研究基于中国急性缺血性卒中降压试验,检测12种生物标志物,分析3405例患者。发现高敏C反应蛋白、补体C3、基质金属蛋白酶-9、肝细胞生长因子和抗磷脂酰丝氨酸抗体升高与主要结局独立相关,且升高标志物数量越多,不良结局风险越高,联合传统风险因素可显著改善风险分层。
要点
- 5种生物标志物升高与主要结局独立相关
- 升高标志物数量与不良结局风险呈梯度关系
- 联合5种标志物可显著改善风险分层
核心结论
- 升高的新型生物标志物数量与主要残疾、死亡和血管事件风险呈清晰梯度关系。
- 联合多种生物标志物可显著改善缺血性卒中患者不良结局的风险分层。
研究设计与样本
- 数据源自中国急性缺血性卒中降压试验,共检测12种信息性生物标志物。
- 纳入3405例参与者,主要结局为3个月死亡和主要残疾(改良Rankin量表评分≥3)的复合结局。
主要发现
- 866例参与者(25.4%)在3个月内发生主要残疾或死亡。
- 高敏C反应蛋白、补体C3、基质金属蛋白酶-9、肝细胞生长因子和抗磷脂酰丝氨酸抗体升高均与主要结局独立相关。
- 与无标志物升高者相比,5种标志物升高者主要结局的调整OR为3.88(95%CI 2.05-7.36),主要残疾为2.81(1.49-5.33),死亡为5.67(1.09-29.52),血管事件为4.00(1.22-13.14)。
关键数值与推荐
- 将5种标志物同时加入含传统风险因素的基础模型,复合结局的净重分类改善为28.5%(p<0.001),综合判别改善为2.2%(p<0.001)。
- 血管事件的净重分类改善为37.0%(p=0.001),综合判别改善为0.8%(p=0.001)。
临床怎么用
- 在缺血性卒中患者中,可考虑检测这5种生物标志物以辅助风险分层。
- 联合传统风险因素与多种生物标志物可能更准确识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the prognostic significance of multiple novel biomarkers in combination after ischemic stroke. METHODS: We derived data from the China Antihypertensive Trial in Acute Ischemic Stroke, and 12 informative biomarkers were measured. The primary outcome was the combination of death and major disability (modified Rankin Scale score ≥3) at 3 months after ischemic stroke, and secondary outcomes included major disability, death, and vascular events. RESULTS: In 3,405 participants, 866 participants (25.4%) experienced major disability or died within 3 months. In multivariable analyses, elevated high-sensitive C-reactive protein, complement C3, matrix metalloproteinase-9, hepatocyte growth factor, and antiphosphatidylserine antibodies were individually associated with the primary outcome. Participants with a larger number of elevated biomarkers had increased risk of all study outcomes. The adjusted odds ratios (95% confidence intervals) of participants with 5 elevated biomarkers were 3.88 (2.05-7.36) for the primary outcome, 2.81 (1.49-5.33) for major disability, 5.67 (1.09-29.52) for death, and 4.00 (1.22-13.14) for vascular events, compared to those with no elevated biomarkers. Simultaneously adding these 5 biomarkers to the basic model with traditional risk factors led to substantial reclassification for the combined outcome (net reclassification improvement 28.5%, p < 0.001; integrated discrimination improvement 2.2%, p < 0.001) and vascular events (net reclassification improvement 37.0%, p = 0.001; integrated discrimination improvement 0.8%, p = 0.001). CONCLUSION: We observed a clear gradient relationship between the numbers of elevated novel biomarkers and risk of major disability, mortality, and vascular events. Incorporation of a combination of multiple biomarkers observed substantially improved the risk stratification for adverse outcomes in ischemic stroke patients.
引用
- Zhong C, Zhu Z, Wang A, et al. Multiple biomarkers covering distinct pathways for predicting outcomes after ischemic stroke. Neurology. 2018. PMID: 30552300. doi:10.1212/WNL.0000000000006717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。